Expert opinion on pharmacotherapy · 2026
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Etessami Julian David, Valenza Carmine, Berton Giachetti Pier Paolo Maria, Crimini Edoardo, Ferraro Emanuela, Marra Antonio, Belli Carmen, Minchella Ida, Zagami Paola, Curigliano Giuseppe, Trapani Dario
Аннотация
INTRODUCTION: Endocrine therapy (ET) remains the backbone of treatment for hormone receptor-positive (HR+), HER2-negative breast cancer. However, resistance, frequently driven by acquired ESR1 mutations detected in up to 40% of patients progressing on first-line ET, represents a major clinical challenge. Oral selective estrogen receptor degraders (SERDs) have been developed to overcome the limitations of first-generation agents and achieve more potent ER targeting.
AREAS COVERED: This review summarizes the mechanism of action of oral SERDs compared with prior endocrine therapies and evaluates clinical evidence supporting their use across treatment settings in HR+/HER2- breast cancer. Literature was identified through systematic searches of PubMed, ClinicalTrials.gov, and major oncology congresses (ASCO, ESMO, SABCS) through early 2026.
EXPERT OPINION: Oral SERDs are reshaping the management of ESR1-mutant disease, with agents such as elacestrant and imlunestrant emerging as standard second-line options. In early-stage disease, trials such as lidERA suggest potential outcome improvements. However, primary resistance to SERD monotherapy remains substantial, highlighting the need for combination strategies. Future directions include ctDNA-guided approaches and expansion into earlier treatment settings.
AREAS COVERED: This review summarizes the mechanism of action of oral SERDs compared with prior endocrine therapies and evaluates clinical evidence supporting their use across treatment settings in HR+/HER2- breast cancer. Literature was identified through systematic searches of PubMed, ClinicalTrials.gov, and major oncology congresses (ASCO, ESMO, SABCS) through early 2026.
EXPERT OPINION: Oral SERDs are reshaping the management of ESR1-mutant disease, with agents such as elacestrant and imlunestrant emerging as standard second-line options. In early-stage disease, trials such as lidERA suggest potential outcome improvements. However, primary resistance to SERD monotherapy remains substantial, highlighting the need for combination strategies. Future directions include ctDNA-guided approaches and expansion into earlier treatment settings.